Join

Compare · CBOE vs CHNA

CBOE vs CHNA

Side-by-side comparison of Cboe Global Markets, Inc. (CBOE) and Loncar China BioPharma ETF (CHNA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CBOE and CHNA operate in n/a (n/a), so they compete in similar markets.
  • CBOE carries a market cap of $13.01B.
  • CBOE has hit the wire 3 times in the past 4 weeks while CHNA has been quiet.
  • CBOE has more recent analyst coverage (25 ratings vs 0 for CHNA).
MetricCBOECHNA
Company
Cboe Global Markets, Inc.
Loncar China BioPharma ETF
Price
$303.52+0.98%
$14.28-0.56%
Market cap
$13.01B
-
1M return
+9.45%
-
1Y return
+43.01%
-
Sector
n/a
n/a
Industry
n/a
n/a
Exchange
NASDAQ
NASDAQ
IPO
2010
n/a
News (4w)
3
0
Recent ratings
25
0
CBOE

Cboe Global Markets, Inc.

Cboe Global Markets, Inc., through its subsidiaries, operates as an options exchange worldwide. It operates through five segments: Options, North American Equities, Futures, European Equities, and Global FX. The Options segment trades in listed market indices. The North American Equities segment trades in listed U.S. and Canadian equities; and offers exchange-traded products (ETP) transaction and ETP listing services. The Futures segment trades in futures. The European Equities segment offers pan-European listed equities transaction services, ETPs, exchange-traded commodities, and international depository receipts, as well as ETP listings and clearing services. The Global FX segment provides institutional foreign exchange (FX) trading and non-deliverable forward FX transactions services. The company has strategic relationships with S&P Dow Jones Indices, LLC; FTSE International Limited; Frank Russell Company; MSCI Inc.; and DJI Opco, LLC. The company was formerly known as CBOE Holdings, Inc. and changed its name to Cboe Global Markets, Inc. in October 2017. Cboe Global Markets, Inc. was founded in 1973 and is headquartered in Chicago, Illinois.

CHNA

Loncar China BioPharma ETF

The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.